CGS-2
Insomnia
Phase IIActive, Recruiting
Key Facts
About Canopy Growth
Canopy Growth's mission is to be a world-leading diversified cannabis and consumer packaged goods company, leveraging its scale and scientific research to deliver therapeutic and wellness products. Its key achievement was securing a landmark $4 billion investment from Constellation Brands in 2018, which fueled rapid expansion and established it as an early industry leader. Current strategy focuses on a rigorous 'Right-Sizing' plan to achieve profitability, divesting non-core assets like BioSteel, and advancing its cannabinoid-based clinical research programs through its Canopy Growth Science division.
View full company profileTherapeutic Areas
Other Insomnia Drugs
| Drug | Company | Phase |
|---|---|---|
| SILENOR | Currax Pharmaceuticals | Approved |
| CLM-IN01 | Closed Loop Medicine | Pre-commercial (UKCA/CE marked) |
| Levroso Long (Diphenhydramine/Melatonin) | NovaMedica | Approved |
| Insomnia Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| HS-10384 | Hansoh Pharma | Phase III |
| CEL-101 (C-122) | Celon Pharma | Phase II |